Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Apple Fitness Plus is one of CNET’s favorite workout apps thanks to its versatility and various exercise selections. It's affordable at only $11 a month, giving you access to thousands of workouts for ...

Two new studies that have been published recently show that people who have been taking weight loss drugs may have encountered an increased risk of serious eye conditions and vision loss.

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

“From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased 50.7 percent, and ...

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.